HEPARAN SULFATE INHIBITORS

1 . A method of treating cancer comprising administering a therapeutically effective amount of a selective modulator of heparan sulfate glycosylation, a modulator of heparan sulfate sulfation, or a selective modulator of heparan sulfate epimerization.

2 . The process of claim 1 , wherein the selective modulator of heparan sulfate biosynthesis inhibits heparan glycosylation.

3 . The process of claim 1 , wherein the selective modulator of heparan sulfate biosynthesis inhibits sulfation of heparan.

4 . The process of claim 1 , wherein the selective modulator of heparan sulfate biosynthesis promotes sulfation of heparan.

5 . The process of claim 1 , wherein the selective modulator of heparan sulfate biosynthesis inhibits epimerization of heparan.

6 . The process of claim 1 , wherein the selective modulator of heparan sulfate biosynthesis promotes epimerization of heparan.

7 . The process of claim 1 , wherein the selective modulator of heparan sulfate is an inhibitor of 6-O sulfation.

8 . The process of any of claim 1 , wherein the selective modulator of heparan sulfate biosynthesis is a non-carbohydrate having a molecular weight of less than 1,000 g/mol.

9 . A method of treating a lysosomal storage disease comprising administering a therapeutically effective amount of a selective modulator of heparan sulfate glycosylation, a modulator of heparan sulfate sulfation, or a selective modulator of heparan sulfate epimerization.

10 . The method of claim 9 , wherein the lysosomal storage disease is selected from mucopolysaccharidosis.

11 . The method of claim 9 , wherein the selective modulator of heparan sulfate glycosylation is an inhibitor of heparan sulfate glycosylation.

12 . The method of claim 9 , wherein the selective modulator of heparan sulfate sulfation is an inhibitor of heparan sulfate sulfation.

13 . The method of claim 9 , wherein the selective modulator of heparan sulfate epimerization is an inhibitor of heparan sulfate epimerization.

14 . The process of claim 9 , wherein the selective modulator of heparan sulfate glycosylation, a modulator of heparan sulfate sulfation, or a selective modulator of heparan sulfate epimerization is an inhibitor of 6-O sulfation.

15 . The process of claim 9 , wherein the selective modulator of heparan sulfate glycosylation, a modulator of heparan sulfate sulfation, or a selective modulator of heparan sulfate epimerization is a non-carbohydrate having a molecular weight of less than 1,000 g/mol.

16 . A compound having the structure:

wherein:

each R is independently H or at least one amino acid,

n is 1-300;

each X is:

R 1 is H, COCH 3 , or SO 3 R 5 ;

R 2 is H, or SO 3 R 5 ;

R 3 is H, or SO 3 R 5 ;

each Y is:

R 4 is H, or SO 3 R 5 ;

each R 5 is independently selected from H and a negative charge;

or physiologically acceptable salts thereof,

and wherein the substituents have one or more of the following ratios:

R 1 ═SO 3 R 5 to R 1 ═COCH 3 is about 0:1 to about 0.2:1;

R 2 ═SO 3 R 5 to R 2 ═H is about 0:1 to about 0.1:1;

R 4 ═SO 3 R 5 to R 2 ═SO 3 R is about 0:1 to about 0.7:1,

R 4 ═SO 3 R 5 to R 2 ═SO 3 R 5 is >1.05; or

R 4 ═SO 3 R 5 to R 4 ═H is about 0:1 to about 0.1:1.

17 . The compound of claim 16 , wherein the ratio of R 4 ═SO 3 R 5 to R 2 ═SO 3 R 5 is about 0:1 to about 0.7:1.

18 . The compound of claim 16 , wherein the ratio of R 4 ═SO 3 R 5 to R 2 ═SO 3 R 5 is about 0:1 to about 0.5:1.

19 . The compound of claim 16 , wherein the ratio of R 4 ═SO 3 R 5 to R 2 ═SO 3 R 5 is about 0:1 to about 0.4:1.

20 . The compound of claim 16 , wherein the ratio of R 4 ═SO 3 R 5 to R 2 ═SO 3 R 5 is >1.05.

21 . The compound of claim 16 , wherein the ratio of R 4 ═SO 3 R 5 to R 2 ═SO 3 R 5 is >1.2.

22 . The compound of claim 16 , wherein less than 10% of R 4 ═SO 3 R 5 .

23 . The compound of claim 16 , wherein each R is at least one amino acid.